跳至主要内容
临床试验/NCT03319524
NCT03319524已完成不适用

Prospective Open Label Clinical and Genetic Testing of Patients With Usher Syndrome

Sensor Technology for Deafblind6 个研究点 分布在 1 个国家目标入组 28 人开始时间: 2017年5月17日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
28
试验地点
6
主要终点
Changes in structures of fundus of the eye-2

研究概览

简要总结

This study is aimed to characterize Russian population of Usher patients.

详细描述

This study is aimed to characterize Russian population of Usher patients.

Tasks:

Stage 1. Formation of the primary cohort of patients. Patients pre-recruiting will be performed based on Deaf-Blind Support Foundation "Con-nection" patient database analysis. Patients with clinically confirmed Usher syndrome will be evaluated according to available data of the clinical examination.

Stage 2. Clinical examination of patients.

Each patient will undergo the following diagnostic procedures according to the unified protocol:

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient fulfill the clinical characteristics for Usher syndrome type I, II or III as defined by the Usher syndrome consortium
  • According to the results of audiometry, hearing loss is moderate or severe (level of acoustic threshold of audibility is 41 decibel and higher).
  • Results of perimetry for each eye show narrowing for 15 degrees or more.
  • Patient is familiar with Participant information sheet
  • Patient signed informed consent form
  • Non-inclusion Criteria:
  • Participation in other clinical trials (or administration of investigational drugs) during 3 months prior inclusion
  • Any conditions limiting compliance (dementia, neuropsychiatric disease, drug and alcohol abuse etc.)
  • Medical history of traumatic injury of eyes, barotrauma, concussion, craniocerebral trauma, cerebrovascular accident

排除标准

  • Patient's refusal from the further participation in the trial
  • Decompensated diabetes mellitus
  • Severe coronary artery disease
  • Chronic infectious disease
  • Patients with malignant tumors including postoperative period, patients receiving chemotherapy and/or radiotherapy

结局指标

主要结局

Changes in structures of fundus of the eye-2

时间窗: Up to 4 weeks

Measured by optical coherence tomography

Changes in visual field

时间窗: Up to 4 weeks

Measured by perimetry

Changes in retinal ganglion cell dysfunction

时间窗: Up to 4 weeks

Measured by electroretinography

Changes in brain visual cortex neural pathways

时间窗: Up to 4 weeks

Measured by visually evoked potentials

Changes in optical refraction

时间窗: Up to 4 weeks

Measured by refractometry

Changes in intraocular pressure

时间窗: Up to 4 weeks

Measured by pneumotonometry

Changes in the lens, cornea, anterior segment of the eye

时间窗: Up to 4 weeks

Measured by biomicroscopy

Changes in hearing-1

时间窗: Up to 4 weeks

Measured by tonal audiometry

Changes in hearing-2

时间窗: Up to 4 weeks

Measured by electronic audiometry (ASSR test)

Changes in efficient sound transmission in the middle ear

时间窗: Up to 4 weeks

Measured by acoustic impedance measurement

Changes in vestibular functions

时间窗: Up to 4 weeks

Measured by vestibulometry

Changes in vestibular reactions

时间窗: Up to 4 weeks

Measured by electronystagmography

Changes in visual acuity

时间窗: Up to 4 weeks

Measured by visometry

Changes in structures of fundus of the eye-1

时间窗: Up to 4 weeks

Measured by ophthalmoscopy

次要结局

未报告次要终点

研究者

发起方
Sensor Technology for Deafblind
申办方类型
Industry
责任方
Sponsor

研究点 (6)

Loading locations...

相似试验